Evidence map›Paper›PMID 28030800›Full record

ArticleOncotarget2017

The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma.

Raphaela Schwentner, David Herrero-Martin, Maximilian O Kauer, Cornelia N Mutz, Anna M Katschnig, Grzegorz Sienski, Javier Alonso, Dave N T Aryee, Heinrich Kovar

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. miRNA signatures in childhood sarcomas and their clinical implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Review
  6. Non-Coding RNAs in Pediatric Solid Tumors.Frontiers in genetics · 2019
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Raphaela SchwentnerChildren´s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna 1090, Austria.
David Herrero-MartinChildren´s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna 1090, Austria.
Maximilian O KauerChildren´s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna 1090, Austria.
Cornelia N MutzChildren´s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna 1090, Austria.
Anna M KatschnigChildren´s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna 1090, Austria.
Grzegorz SienskiInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna Biocenter Campus, 1030 Vienna, Austria.
Javier AlonsoUnidad de Tumores Sólidos Infantiles, Instituto de Investigación de Enfermedades Raras, ISCIII, Ctra, Majadahonda-Pozuelo Km 2, 28220 Madrid, Spain.
Dave N T AryeeChildren´s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna 1090, Austria.
Heinrich KovarChildren´s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna 1090, Austria.
St. Anna Children's Cancer Research InstituteSt Anna Children's Hospital · ATAustrian Academy of Sciences · ATInstituto de Investigación de Enfermedades Raras · ESMedical University of Vienna · AT

Funding

Austrian Science Fund FWF I 1225
6 · The paper itself

Abstract

MicroRNAs serve to fine-tune gene expression and play an important regulatory role in tissue specific gene networks. The identification and validation of miRNA target genes in a tissue still poses a significant problem since the presence of a seed sequence in the 3'UTR of an mRNA and its expression modulation upon ectopic expression of the miRNA do not reliably predict regulation under physiological conditions. The chimeric oncoprotein EWS-FLI1 is the driving pathogenic force in Ewing sarcoma. MiR-17-92, one of the most potent oncogenic miRNAs, was recently reported to be among the top EWS-FLI1 activated miRNAs. Using a combination of AGO2 pull-down experiments by PAR-CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation) and of RNAseq upon miRNA depletion by ectopic sponge expression, we aimed to identify the targetome of miR-17-92 in Ewing sarcoma. Intersecting both datasets we found an enrichment of PAR-CLIP hits for members of the miR-17-92 cluster in the 3'UTRs of genes up-regulated in response to mir-17-92 specific sponge expression. Strikingly, approximately a quarter of these genes annotate to the TGFB/BMP pathway, the majority mapping downstream of SMAD signaling. Testing for SMAD phosphorylation, we identify quiet but activatable TGFB signaling and cell autonomous activity of the BMP pathway resulting in the activation of the stemness regulatory transcriptional repressors ID1 and ID3. Taken together, our findings shed light on the complex miRegulatory landscape of Ewing Sarcoma pointing miR-17-92 as a key node connected to TGFB/BMP pathway.

Indexed as

Gene Expression Regulation, Neoplastic3' Untranslated RegionsBone Morphogenetic ProteinsCell Line, TumorGene Expression ProfilingGenetic Predisposition to DiseaseHumansMicroRNAsMutationOligonucleotide Array Sequence AnalysisOncogene Proteins, FusionProto-Oncogene Protein c-fli-1Reverse Transcriptase Polymerase Chain ReactionRNA-Binding Protein EWSRNA, Long NoncodingSarcoma, Ewing3' Untranslated RegionsBone Morphogenetic ProteinsEWS-FLI fusion proteinMicroRNAsMIR17HG, humanOncogene Proteins, FusionProto-Oncogene Protein c-fli-1RNA-Binding Protein EWSRNA, Long NoncodingTransforming Growth Factor betaEwing sarcomaEWS-FLI1miR-17-92PAR-CLIPTGFB/BMP pathway

Identifiers

PMID28030800
PMCPMC5355239
OpenAlexW2563797303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.